Latest News
-
Tuesday - February 11, 2020
Bayer and Nuvisan create new research unit in Berlin
Nuvisan to establish full-fledged research center with around 400 jobs in Berlin / Transaction to contribute to further strengthening healthcare cluster in Berlin / Bayer to retain significant research activities and headquarters for the company’s Pharmaceuticals Division in Berlin » more
-
Monday - February 10, 2020
Not intended for U.S. and UK Media
Bayer announces Phase III trials with new aflibercept 8mg formulation » more
-
Monday - February 10, 2020
Bayer, Meiogenix collaborate to accelerate agricultural innovation through the development of unique technologies » more
-
Friday - February 7, 2020
Bayer expands commitment to transparency in 2020
New online access in April 2020 to genetically modified (GM) seed regulatory submission documents, plus educational materials on GM seeds and plant breeding / Launching pilot to allow visitors to experience science and facilities in action » more
-
Monday - February 3, 2020
Sustainability efforts recognized:
CDP again rates Bayer as one of the leading international companies for water management
Top assessment for 10 years in succession / Bayer only DAX company with best rating both in climate change and water security » more
-
Friday - January 31, 2020
Bayer Welcomes U.S. Environmental Protection Agency’s Reaffirmation that Glyphosate Is Safe to Use, Not Carcinogenic
“Decision of EPA corresponds to the long-standing assessments of leading international health authorities”, says Liam Condon, Bayer Board Member / The Amicus brief of the U.S. Department of Justice in the Hardeman case also support Glyphosate´s safety » more
-
Friday - January 31, 2020
Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for darolutamide as a new treatment for men with non-metastatic castration-resistant prostate cancer
CHMP opinion is based on Phase III ARAMIS trial data evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT / Final decision from the European Commission is anticipated within the coming months » more
-
Thursday - January 30, 2020
Not intended for U.S. and UK Media - 1st World Neglected Tropical Diseases Day
Bayer application for nifurtimox to treat pediatric patients with Chagas disease submitted for approval in US
New formulation for weight-adjusted treatment of pediatric Chagas patients age 0-18 targets most vulnerable patient group / Submission based on results of CHICO (CHagas disease In Children treated with NifurtimOx) phase III clinical study of nifurtimox in pediatric patients with Chagas disease as well as pre-clinical data / Fight against Neglected Tropical Diseases part of Bayer’s Sustainability Strategy » more
-
Thursday - January 30, 2020
Not intended for U.S. and UK Media – Updated results of Phase III trial show:
Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer
Full data to be presented at upcoming scientific meeting » more
-
Tuesday - January 28, 2020
Aid package to combat coronavirus in China:
Bayer to donate medicines and money with a total value of approximately EUR 1.5 million
CEO Werner Baumann: “We want to help people in the affected regions quickly and effectively” » more
-
Thursday - January 23, 2020
Bayer appoints Bijoy Sagar as new Chief Information Technology & Digital Transformation Officer
Daniel Hartert to leave Bayer after 12 years at the company » more
-
Thursday - January 23, 2020
Not intended for U.S. and UK Media
Bayer submits application to European Medicines Agency for pre-filled syringe to administer eye medication Eylea® » more
-
Thursday - January 23, 2020
Not intended for U.S. and UK Media
Bayer receives approval for darolutamide in Japan
Marketing authorization granted for the treatment of men with non-metastatic castration-resistant prostate cancer » more
-
Tuesday - January 21, 2020
Inclusion in the Bloomberg Gender-Equality Index
Bayer a global leader in diversity and inclusion » more
-
Monday - January 20, 2020
Not intended for U.S. and UK Media
Bayer to showcase new data including research in immuno- and precision oncology at ASCO GI Cancers Symposium 2020
Data to include early analyses of regorafenib across HCC, CRC and GI cancers, including Phase Ib data in combination with immuno-oncology therapies / New analysis of efficacy and safety from the NAVIGATE trial for larotrectinib in patients with TRK fusion cancer with gastrointestinal tumors will be presented » more
-
Monday - January 20, 2020
CDP publishes new ranking:
Bayer confirms leading international position as a sustainable company taking climate action
Chairman of the Board of Management, Baumann: “As a leading innovation company, we will drive forward a reduction in greenhouse gases throughout our entire value chain” / Numerous investors factor CDP ratings into investment decisions / Bayer listed as a leading company by CDP every year since 2005 » more
-
Thursday - January 16, 2020
Bayer and WuXi Biologics enter into an agreement on a Leverkusen drug product plant » more
-
Monday - January 13, 2020
Not intended for U.S. and UK Media
Bayer and Daré Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene®
Underlining Bayer’s commitment in the field of women’s health / Potential commercial milestone payments of up to USD 310 million and tiered royalties on net sales in the double-digit range » more
-
Friday - January 10, 2020
Bayer and Azitra partner to harness the human skin microbiome as a source for new natural skin care products for sensitive and eczema-prone skin
Skin microbiome plays a crucial role in maintaining and restoring healthy human skin / Azitra targets skin “friendly” bacteria to solve the challenges of adverse skin conditions and diseases / Bayer to develop new natural skin care products based on suited skin microbiome bacteria » more
-
Thursday - January 9, 2020
Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection
Bayer TV